NASDAQ:FATE Fate Therapeutics Q4 2025 Earnings Report $2.58 +0.06 (+2.18%) As of 03:28 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.27Consensus EPS -$0.27Beat/MissMet ExpectationsOne Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$1.37 millionExpected Revenue$1.20 millionBeat/MissBeat by +$171.00 thousandYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ4 2025Date2/26/2026TimeBefore Market OpensConference Call DateThursday, February 26, 2026Conference Call Time7:00AM ETUpcoming EarningsFate Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K)Annual report Fate Therapeutics Earnings HeadlinesFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus NephritisAugust 14 at 7:00 AM | globenewswire.comFate Therapeutics, Inc.: Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 13 at 1:29 PM | finanznachrichten.deBuffett's Final Warning: "The Dollar Is Going to Hell"The US just hit $39 trillion in debt. Interest alone is now over $1 trillion a year, more than the entire defense budget. There's no way to tax our way out. No way to cut our way out. The government has exactly one move left: Pump trillions into AI to outgrow the debt. And the asset class profiting from these trillions in spending. BlackRock is buying. Goldman Sachs is buying. Gartner is calling it the next decade defining boom. The last time a similar setup formed, early investors saw gains of up to 12,480%. I've put together a workshop breaking this down in detail. I'll name the asset class and show you exactly how to profit from this $39 trillion debt crisis.August 14 at 1:00 AM | Decentralized Masters (Ad)Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesAugust 13 at 8:30 AM | globenewswire.comFate Therapeutics (FATE) Projected to Post Earnings on TuesdayAugust 10, 2026 | americanbankingnews.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)August 3, 2026 | globenewswire.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE) is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access. Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development. Key programs include FT596, an NK cell candidate targeting CD19‐positive lymphoid malignancies; FT538, an NK cell therapy engineered for acute myeloid leukemia; and FT819, an iPSC‐derived CAR T‐cell product for multiple myeloma. The company’s platform also supports early‐stage efforts in autoimmune and inflammatory diseases, with preclinical programs exploiting novel mechanisms of immune modulation. Founded in 2007 and headquartered in La Jolla, California, Fate Therapeutics completed its initial public offering on the Nasdaq Stock Market in December 2013. The company has established strategic collaborations with pharmaceutical partners, including Biogen and Janssen Biotech, to advance selected cell therapy candidates. Clinical trials are underway across North America and in select international sites. Under the leadership of President and Chief Executive Officer Scott Wolchko, M.D., Fate Therapeutics continues to expand its manufacturing capabilities and clinical footprint. The company’s global efforts seek to bring standardized, off‐the‐shelf cell therapies to patients with limited treatment options, addressing unmet medical needs in oncology and immune dysregulation.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
